This site is intended for healthcare professionals
News

Phase III PEGASUS study of APL 2 shows consistent impact in paroxysmal nocturnal hemoglobinuria.- Apellis Pharma

Read time: 1 mins
Last updated:15th Jun 2020
Published:14th Jun 2020
Condition: Paroxysmal Nocturnal Haemoglobinuria
Type: drug
Register free for full access to medthority.com